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Abstract 
A reversed phase-high performance liquid chromatography (RP-HPLC) method was developed for the 
determination of Loxapine drug in tablet dosage form. The developed method was validated by measuring linearity, 
precision, limit of detection (LOD), robustness and ruggedness, drug recovery and for system suitability. Water and 
acetonitrile in the ratio 55:45 v/v was the mobile phase, C18 column (250 mm x 4.6 mm x 5 µm) as a stationary phase, and 
265 nm was the detection wavelength. The HPLC system was operated in isocratic mode. The measured retention time of 
Loxapine drug was 6.88 minutes and the limit of detection was 0.035 µg/ml, respectively. The linearity measured in the 
range 10-100 µg/ml had a correlation coefficient of 0.999. The results of the parameters precision, robustness, recovery and 
formulation assay indicate that the developed method is a very good tool for the analysis of Loxapine drug in bulk and 
capsule dosage form. 
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1. Introduction 
Loxapine, a member of the dibenzoxazepine class, 
is an antipsychotic drug mainly used for the treatment of 
schizophrenia [1]. Its systematic (IUPAC) name is 2-
chloro-11-(4-methylpiperazin-1-
yl)dibenzo[b,f][1,4]oxazepine and the chemical formula is 
C18H18ClN3O [2, 3]. The Loxapine molecular structure is 
shown in Fig. 1 and its molecular weight is 327.81 g/mol 
[2, 3]. 
 
 
 
Fig. 1: The chemical structure of Loxapine. 
 
Loxapine was investigated alone in plasma [4, 5], 
human plasma [6, 7] and in combination with other drugs 
[8-15]. It was also studied with other drugs in plasma [8], 
human plasma [9], with its metabolites in plasma [10], 
human plasma [11, 12], rat plasma [13], and serum and 
urine [14]. Various analytical techniques have been 
employed to determine Loxapine. They were high 
performance liquid chromatography (HPLC) [4, 6-8, 10-
11], HPLC - MS/MS [9], HPLC – MS [12], Liquid 
Chromatography (LC)-MS/MS method [13] gas liquid 
chromatography (GLC) [14] and capillary zone 
electrophoresis [15]. 
In this paper, we have developed a method for 
Loxapine in capsule dosage form and validated it following 
the ICH guidelines [16, 17] with the parameters linearity, 
limit of detection, precision, robustness, ruggedness and 
system stability. The developed method is fast, cost 
effective because easily available chemicals are used as 
mobile phase and can be used for the analysis of 
commercially available drugs both in laboratories and 
industries. 
 
2. Materials and methods 
The chemicals and reagents used for the present 
study were of HPLC grade. Methanol, water (pH between 5 
and 8) and acetonitrile were purchased from Merck 
Specialties Private Ltd., Mumbai, India. 
A PEAK HPLC system operated in isocratic mode 
was employed for the reported work. It was equipped with 
a LC 20AT pump and a variable wavelength programmable 
ultraviolet (UV)-Visible detector (SPD-10AVP).  As a 
stationary phase, Chromosil C18 column (250 x 4.6 mm, 5 
μm particle size) was used. The samples were injected with 
a 20 μL Hamilton syringe. Degassing of the mobile phase 
was carried out using an ultrasonic bath sonicator (Loba).  
Weighing of the samples was done with a Denver (SI234) 
balance. Chromatograms were recorded and integrated 
using PEAK software. The obtained data was analyzed 
using Microsoft Excel. The absorption wavelength of 
Loxapine was determined using an ultraviolet (UV) - 
Visible spectrophotometer (Techcomp UV 230D6) with 
HITACHI software. 
2.1 Preparation of stock solution 
The stock solution for the present study was 
prepared from a 10 mg of Loxapine drug. After weighing it 
was dissolved in 10 ml of mobile phase in a 10 ml 
volumetric flask.  The solution was sonicated for 2 minutes 
to dissolve the drug completely. After cooling, it was 
filtered with a 0.45 µm nylon membrane ultipore filter 
paper.  
A 1000 µg/ml stock solution was prepared and 
from this, 2 ml was further diluted to 20 ml and obtained a 
stock concentration of 100 µg/ml solution.  By selective 
dilution, required concentrations were prepared from the 
stock solution. 
2.2. Method development 
The RP-HPLC conditions like mobile phase 
composition, flow rate, wavelength were optimized for a 
sharper chromatogram peak and to fulfill the ICH guide 
lines. Firstly, mobile phase volume ratio was developed. In 
general, the mobile phase will be chosen by controlled trial 
and error method. This mainly depends on the suitability to 
the drug sample to be analyzed, cost-effectiveness and 
from the information available from the literature. Here, 
standard organic solvents methanol, acetonitrile and water 
were tested separately and in combination as a mobile 
phase. From the observation, water and acetonitrile 
combination showed better results.  Then different volume 
ratios of water and acetonitrile were tried and finally the 
55: 45 v/v gave a sharper chromatogram, high theoretical 
plates and low tailoring factor. Thus, we choose this as 
optimal mobile phase for the present study. After several 
iterations (trials) and chromatographic runs, pH of 6.6 with 
addition sodium acetate resulted in a better peak symmetry 
and good signal to noise (S/N) ratio. 
The active pharmaceutical ingredient (API) 
concentration chosen was 60 µg/ml. This was also used as 
standard concentration as it was the optimum concentration 
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from the Beer Lambert’s law obtained from the linearity 
range measurements. The pump pressure was noted down 
during the development phase and the optimum value was 
7.5 MPa for the standard solution. The flow rate used for 
the reported results was 0.8 ml/min. 
The run time was selected after checking for the 
interferences from the excipients. The optimum conditions 
obtained during the method development and used for 
validation of various parameters were: mobile phase - 
water: acetonitrile (55: 45 v/v); detection wavelength - 265 
nm; stationary phase column - C18 column (250 mm x 4.6 
mm, 5 µm); pH of the mobile phase - 6.6 with sodium 
acetate; API concentration - 60 µg/ml; flow rate - 0.8 
ml/min; pump pressure - 7.5 ± 0.5 Mpa and runtime - 10 
minutes. 
 
3. Results and discussion 
In order to determine the best wavelength of 
maximum absorption of Loxapine spectrophotometric 
method was used. The wavelength was scanned in the 
range of 200 nm - 400 nm. The maximum absorption was 
observed at 265 nm (Fig. 2). 
 
 
 
Figure 2:  Absorption spectrum of loxapine with wavelength (nm) vs. absorbance (%). 
 
The parameters described below have been 
validated for the developed method in accordance with the 
International Conference and Harmonization (ICH) 
guidelines [13, 14]. The general acceptance criteria is that 
residual standard deviation (RSD) of peak areas should be 
less than 2%. Further the system suitability was evaluated 
from the theoretical plate number and tailing factor. The 
theoretical plate (TP) numbers should be at least 2500 for 
each peak and it was 20345 for the standard solution, a 
factor of 8.1 more than the recommended value. The tailing 
factor value has to be less than 2, which was 1.12 for the 
presented results. In Fig. 3 shown was the chromatogram of 
Loxapine obtained for the standard solution with optimized 
conditions. 
 
 
Figure 3: Chromatogram of Loxapine from formulation assay. The retention time is 6.88 minutes. 
 
3.1 Linearity 
The linearity of the peak areas was determined for 
10 different concentrations of Loxapine in the 10-100 
µg/ml range.  The calibration graph was obtained by 
plotting peak areas as ordinates and the corresponding ten 
concentrations (µg/ml) as abscissa (fig. 4). The linear 
regression y = mx + c, where ‘m’ the slope of the line and 
‘c’ the y-intercept in the fit to the data. The linear 
regression was found to be precise from the correlation 
coefficient, R
2
 = 0.999. 
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Fig. 4: Linearity results of Loxapine. 
 
3.2 Precision  
A widely validated parameter for drugs was the 
repeatability for over a period of time through intra-day 
(same day) and inter-day (different days) precision studies. 
Here, the intra-day precision as well as inter-day precision 
was studied at 60 µg/ml of Loxapine (Table 1).  The data 
given in Table 1 from intra-day precision and inter-day 
precision were mean normalized area. The mean given was 
obtained from the normalized area of the samples. The 
normalization was done with respect to the area of one of 
the six (n=6) samples. Also, given in Table 1 were standard 
deviation (SD) and relative standard deviation (RSD) of the 
precision measurements. The RSD of the samples for both 
intra-day (1.31) and inter-day (1.73) measurements 
conclude that the method was precise. 
 
Table 1: Results of intra-day, inter-day precision and ruggedness for Loxapine. 
Parameter 
Concentration 
(µg/ml) (n=6) 
Normalized Area Mean 
± SD 
RSD 
Intra-day precision 60 1.011 ± 0.013 1.31 
Inter-day precision 60 1.008 ± 0.018 1.73 
Ruggedness 60 0.989 ± 0.178 1.79 
 
3.3 Ruggedness  
Loxapine concentration of 60 µg/ml was also used 
to study the ruggedness of the method. In the present work, 
this was verified by two different analysts for the same 
concentration of Loxapine. Six (n = 6) samples in total 
were analyzed. The effect of these changes on the peak 
area was evaluated by calculating the RSD. The results 
were given Table 1. The RSD value obtained was less than 
2% indicating the ruggedness of the procedure. 
3.4 Limit of detection (LOD) and Limit of 
quantification (LOQ)  
The limit of detection and limit of quantification 
play an important role in determining the sensitivity of the 
method developed for the studied sample. Detection and 
quantification limits were calculated from the calibration 
equations obtained from the experiment. This was based on 
the signal to noise (S/N) ratio, repeatability and system 
suitability. The lowest concentration where the S/N ratio 
was better was chosen as the limit of detection (LOD). 
Then LOQ was determined from the equation, LOQ = 3.3 
LOD. For Loxapine, the values for limit of detection was 
0.035 µg/ml and the limit of quantification was 0.1 µg/ml, 
respectively. 
3.5 Robustness  
The robustness of the developed method was very 
important in determining the effects of variations to the 
instrumental parameters. This was done by deliberately 
changing the mobile phase volume ratio (<10%), pH of the 
solution (10%) and detection wavelength (<1%). The 
changes observed in the peak areas with respect to the peak 
area of the optimized conditions were given in Table 2. 
Table 2: Results of robustness data of Loxapine for three parameters 
Parameter Change Peak Area (mAU) % of change in peak  area RSD 
Standard No change 569851 --- 
Mobile phase 
Water : Acetonitrile 
60 : 40 v/v 580195 1.81 
50 : 50 v/v 572066 0.38 
pH 
6.5 576337 1.13 
6.7 574355 0.79 
Wavelength 
260 nm 562069 -1.36 
270 nm 579996 1.78 
 
The percentage change of peak areas was 
calculated for each changed parameter and was found to be 
less than 2% (Table 2). The method was robust at 10% 
variation of the mobile phase composition and about a 
factor of 5 changes in peak areas was observed between the 
changed concentrations of mobile phase. The change in the 
pH of the solution resulted in negligible changes in the 
peak area. About a percent decrease in wavelength from the 
central value showed decrease in the peak area. But, a 
percentage increase in wavelength from the central 
wavelength value showed increase in the peak area. This 
proved to be a sensitive parameter. The above 
measurements indicate robustness of the developed 
method. 
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3.6 Recovery  
To check for the accuracy of the proposed 
method, recovery experiments were carried out by standard 
addition technique by adding a known amount of standard 
at three different levels (50%, 100% and 150%) to the 
sample. The analysis of each level was repeated three times 
(n = 3). The results were given in Table 3. For example, if 
the target amount was 20 µg/ml, 50% of the target solution 
was spiked with 10 µg/ml solution making the total 
concentration as 30 µg/ml. Now area of the peak 40 µg/ml 
is compared with the standard 60 µg/ml solution peak. 
Then the two areas are compared, from which 
concentration was measured for the percentage recovery 
(Table 3).  Finally, the percentage recovery of Loxapine 
was compared with the actual amounts. The good recovery 
of the product in the range of 99.7% to 100.18% suggests 
the high accuracy of the method. The percentage error for 
recovery was given in last column. 
Table 3: Recovery study results of loxapine at three percentage levels. 
% added 
Target 
concentration 
(µg/ml) (n=3) 
Spiked 
concentration 
(µg/ml) 
Final 
concentration 
(µg/ml) 
Concentration 
Obtained 
Mean ± SD 
RSD or 
CV (%) 
 
Recovery (%) 
Mean ± SD 
Error 
a
(%) 
50% 20 10 30 30.05 ± 0.38 1.27 100.18 ± 1.28 0.74 
100% 20 20 40 40.06 ± 0.64 1.58 100.15 ± 1.59 0.92 
150% 20 30 50 49.85 ± 0.48 0.95 99.7 ± 0.95 0.55 
a % Error = RSD/√n.  No. of trails, n = 3 
 
3.7 Formulation assay  
The assay of the proposed method was applied to 
Loxapine available in commercial tablets in fixed dosage 
form (Loxapac).  Twenty capsules of Loxapac tablets were 
weighed and powdered. The average weight of the powder 
was 88 mg. The capsule powder equal to 10 mg of the drug 
was dissolved in 100 ml of methanol. From the 
concentration of 100 µg/ml solution, 60 µg/ml was 
prepared and used for formulation assay studies. Assay 
results of Loxapine expressed as a percentage of label 
claim was in good agreement within 90 to 100% of the 
label claim (Table 4). In the chromatogram only one 
dominant peak was observed. There was no interference 
from other excipients and their peaks were negligible (Fig. 
3).  
Table 4: Formulation assay of Loxapine 
Formulation Form Dosage Concentration Amount found % Assay 
Loxapac Capsule 50 mg 60 µg/ml 59.46 99.09 
 
4. Conclusion 
In conclusion, Loxapine was determined in 
capsule dosage form using RP-HPLC method. The 
developed method provided a simple, precise and accurate 
way for the determination of Loxapine.   The developed 
method facilitates faster analysis of Loxapine with reduced 
runtime and the statistical analysis of the parameters prove 
that the method provides good recovery, robustness and 
precision. The method and the systems were suitable for 
routine analysis of Loxapine in capsule dosage form. 
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